• 1 In 300 People In The U.S. Is Living With HIV. That’s Not Okay With Jeff Galvin.

    By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy.

  • Accelerating Drug Development With Real World Data

    Think real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are leveraging RWD in their formative stages, long before entering the clinic, to drive critical efficiencies in drug discovery and development.

  • Data-Driven Biopharma Leadership

    Knowing when it’s time to raise funds, fortify a CMC initiative, hire a chief regulatory or commercial officer, or make virtually any other big money move in biopharma isn’t art, it’s science. Business progress, as in scientific progress, is a data-driven exercise.

  • Legal And IP Protection For New Biotechs

    Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs. 

  • Establishing A Research Function In Biopharma

    When it was time to double-down on development efforts to feed its pipeline of biologics, Horizon Therapeutics turned to Big Biopharma veteran Robert Stoffel, Ph.D. to lead the effort. Stoffel joined us for an episode of the Business of Biotech podcast to share how he did it.

  • The DEI Value Proposition

    The value of DEI initiatives sometimes get lost in their feel-good, altruistic intent. Not at Rocket Pharmaceuticals, where purposeful and specific equity and inclusion exercises pay dividends in the form of a diverse, talented, and committed workforce. President & COO Kinnari Patel, PharmD explains.

  • The Immigrant Approach To Biotech Formation

    Flagship Pioneering General Partner Avak Kahvejian, Ph.D., says successfully ideating new biotech companies — which Flagship has done in spades — requires the curiosity, skepticism, and paranoia of a new inhabitant in foreign land. Oh, and a little bit of machine learning won’t hurt.

  • Inside M&A With Bill Symonds

    On episode 143 of the Business of Biotech, Enzyvant CEO Bill Symonds, Pharm.D. takes us inside the rationale and execution of last year’s Enzyvant/Altavant merger.

  • Where Science Leads, Business Follows

    Learn how science, rather than market and investor expectations, directed Francois Rieger’s oversight of the Medsenic/Bone Therapeutics merger.

  • The Hybrid Face Of Biopharma

    What came first, the development platform or the therapeutic asset? To a growing class of biotechs, it doesn’t even matter.

  • Tech-Heavy Drug Discovery Yields Deep Pipeline

    The Business of Biotech caught up with Recursion Co-Founder & CEO Chris Gibson, Ph.D. on the heels of the company launching four clinical trials in just three quarters. That progress was built on a foundation of rapid, machine-enabled drug discovery.

  • Why RNA Is Good For Business

    RNA’s not just good science, it’s good for business. No one understands this better than Nutcracker Therapeutics’ Dr. Geoff Nosrati, whose Ph.D. in Biochemistry and Molecular Biology supports him in his current role as Chief Business Officer at Nutcracker Therapeutics.

  • Where Oncology Treatment Goes Next

    Dr. Steve Davidsen’s long tenure leading drug discovery efforts at AbbVie offers rare perspective into how far oncology treatment has come, and what’s needed to continue its progress.

  • Anatomy Of A Biopharma VC Deal

    Ray Therapeutics CEO Paul Bresge and 4BIO Capital Managing Partner Dmitri Kuzmin, Ph.D. break down the deal that launched Ray and ponder the risk of a mission-driven biopharma CEO.

  • The Rise Of Computational Biology In Biopharma

    I thought I’d peel a layer off the onion to reveal a trend that’s gaining momentum and having a positive impact during a somewhat negative biopharma news cycle: computational biology.


Matthew Pillar

Matthew Pillar is chief editor at Bioprocess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.

Connect with Pillar on LinkedIn at